94.84
price down icon5.87%   -5.91
after-market After Hours: 94.00 -0.84 -0.89%
loading
Revvity Inc stock is traded at $94.84, with a volume of 2.11M. It is down -5.87% in the last 24 hours and down -13.20% over the past month. Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See More
Previous Close:
$100.75
Open:
$98.85
24h Volume:
2.11M
Relative Volume:
2.30
Market Cap:
$11.39B
Revenue:
$2.72B
Net Income/Loss:
$254.30M
P/E Ratio:
45.89
EPS:
2.0665
Net Cash Flow:
$564.37M
1W Performance:
-10.21%
1M Performance:
-13.20%
6M Performance:
-23.49%
1Y Performance:
-6.73%
1-Day Range:
Value
$93.54
$99.00
1-Week Range:
Value
$93.54
$107.16
52-Week Range:
Value
$93.54
$129.50

Revvity Inc Stock (RVTY) Company Profile

Name
Name
Revvity Inc
Name
Phone
781-663-6900
Name
Address
77 4TH AVENUE, WALTHAM
Name
Employee
11,000
Name
Twitter
Name
Next Earnings Date
2025-01-31
Name
Latest SEC Filings
Name
RVTY's Discussions on Twitter

Compare RVTY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
RVTY
Revvity Inc
94.84 11.39B 2.72B 254.30M 564.37M 2.0665
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
437.91 165.21B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
181.77 130.05B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
393.73 31.91B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
103.00 29.38B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
154.73 27.28B 15.41B 1.37B 2.11B 7.50

Revvity Inc Stock (RVTY) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-10-25 Downgrade Bernstein Outperform → Mkt Perform
Dec-13-24 Upgrade BofA Securities Neutral → Buy
Oct-15-24 Upgrade Barclays Equal Weight → Overweight
Aug-28-24 Initiated Wells Fargo Equal Weight
Jul-08-24 Initiated Leerink Partners Outperform
Jun-03-24 Resumed Jefferies Hold
Jan-16-24 Downgrade UBS Buy → Neutral
Jan-04-24 Upgrade Evercore ISI In-line → Outperform
Dec-19-23 Initiated Wells Fargo Equal Weight
Dec-13-23 Initiated Wolfe Research Peer Perform
Sep-28-23 Initiated Bernstein Outperform
Jul-19-23 Initiated Raymond James Outperform
May-23-23 Resumed Goldman Buy
View All

Revvity Inc Stock (RVTY) Latest News

pulisher
Apr 03, 2025

Revvity Q1 2025 Earnings Preview: CEO and CFO to Detail Financial Performance - Stock Titan

Apr 03, 2025
pulisher
Apr 03, 2025

FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo - Yahoo

Apr 03, 2025
pulisher
Apr 02, 2025

FDA greenlights Revvity’s TB diagnostic platform By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Revvity (RVTY) Gains FDA Approval for Automated TB Test - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

What's Going On With Revvity Stock Today? - Benzinga

Apr 02, 2025
pulisher
Apr 02, 2025

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - 01net

Apr 02, 2025
pulisher
Apr 02, 2025

Evercore ISI Adjusts Revvity Price Target to $125 From $138, Maintains Outperform Rating - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

FDA Approves Revvity’s Improved Automated Latent Tuberculosis Test - Medical Product Outsourcing

Apr 02, 2025
pulisher
Apr 02, 2025

Revvity gets FDA nod for its automated tuberculosis test (RVTY:NYSE) - Seeking Alpha

Apr 02, 2025
pulisher
Apr 02, 2025

Revvity Says FDA Approves Auto-Pure 2400 Liquid Handler for Tuberculosis Test - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

FDA greenlights Revvity’s TB diagnostic platform - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - Zacks Investment Research

Apr 02, 2025
pulisher
Apr 02, 2025

Game-Changing TB Test: Revvity's New FDA-Approved System Cuts Testing Time by 70% - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Pictet Asset Management Holding SA Has $125.17 Million Holdings in Revvity, Inc. (NYSE:RVTY) - MarketBeat

Apr 02, 2025
pulisher
Mar 31, 2025

Is Revvity Stock Underperforming the Nasdaq? - MSN

Mar 31, 2025
pulisher
Mar 28, 2025

High Content Screening/Imaging Technology Analysis and Global Market Forecasts 2025-2029 with Danaher, Revvity, Thermo Fischer Scientific, Agilent Technologies and Yokogawa LeadingResearchAndMarkets.com - Bluefield Daily Telegraph

Mar 28, 2025
pulisher
Mar 28, 2025

Is Revvity Stock Underperforming The Nasdaq? - Barchart

Mar 28, 2025
pulisher
Mar 27, 2025

Is Revvity Gaining or Losing Market Support? - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Revvity Expands Alliance With Genomics England To Drive Research Into Newborn Genomic Sequencing in England - Technology Networks

Mar 27, 2025
pulisher
Mar 25, 2025

Revvity Stock Tumbles Despite Expanding Genomics England Alliance - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years - Yahoo Finance

Mar 25, 2025
pulisher
Mar 21, 2025

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - BioSpace

Mar 21, 2025
pulisher
Mar 20, 2025

Revvity Expands Alliance with Genomics England -March 20, 2025 at 02:10 pm EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Massive Breakthrough: Revvity's 100K Newborn Genetic Screening Program Targets 200 Rare Diseases - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

May 16th Options Now Available For Revvity (RVTY) - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Simply Wall St

Mar 20, 2025
pulisher
Mar 19, 2025

Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Mar 19, 2025
pulisher
Mar 19, 2025

Revvity's AI-Powered Cellular Imaging & Research Antibodies - openPR

Mar 19, 2025
pulisher
Mar 17, 2025

KeyBanc Adjusts Price Target on Revvity to $145 From $135, Maintains Overweight Rating - MarketScreener

Mar 17, 2025
pulisher
Mar 12, 2025

Learn to Evaluate (RVTY) using the Charts - Stock Traders Daily

Mar 12, 2025
pulisher
Mar 11, 2025

Revvity at Leerink Global Healthcare Conference: Strategic Resilience Amid Challenges - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Jones Financial Companies Lllp Acquires 1,228 Shares of Revvity, Inc. (NYSE:RVTY) - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

Mutual of America Capital Management LLC Cuts Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

PerkinElmer Stock Price | RVTY Stock Quote, News, and History - Markets Insider

Mar 07, 2025
pulisher
Mar 06, 2025

Sanctuary Advisors LLC Purchases Shares of 1,872 Revvity, Inc. (NYSE:RVTY) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay - Technology Networks

Mar 06, 2025
pulisher
Mar 06, 2025

Revvity, Inc. (NYSE:RVTY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Revvity Expands Measles Testing Accessibility with EUROIMMUN Anti-Measles Virus ELISA 2.0 - Lab Manager Magazine

Mar 05, 2025
pulisher
Mar 05, 2025

Revvity's (NYSE:RVTY) Solid Earnings Have Been Accounted For Conservatively - Yahoo Finance

Mar 05, 2025
pulisher
Mar 04, 2025

What Does the Market Think About Revvity? - Benzinga

Mar 04, 2025
pulisher
Mar 04, 2025

Private Advisor Group LLC Grows Stock Holdings in Revvity, Inc. (NYSE:RVTY) - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Revvity Says Euroimmun Gets CE Mark for Measles Antibody Detection -March 03, 2025 at 10:28 am EST - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

High-Throughput Screening Technology Analysis and Global - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

High-Throughput Screening Technology Analysis and Global Markets 2021-2024 & 2025-2029 with Danaher, Thermo Fisher Scientific., Charles River Laboratories, Revvity and Bio-Rad Laboratories Leading - Yahoo Finance

Mar 03, 2025
pulisher
Mar 03, 2025

Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance

Mar 03, 2025
pulisher
Mar 03, 2025

Jefferies raises Revvity stock price target to $130, maintains Hold - MSN

Mar 03, 2025
pulisher
Mar 01, 2025

Is Revvity, Inc.'s (NYSE:RVTY) Stock Price Struggling As A Result Of Its Mixed Financials? - Simply Wall St

Mar 01, 2025
pulisher
Feb 28, 2025

3 Reasons to Sell RVTY and 1 Stock to Buy Instead - Yahoo Finance

Feb 28, 2025
pulisher
Feb 27, 2025

Principal Financial Group Inc. Sells 4,253 Shares of Revvity, Inc. (NYSE:RVTY) - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

New York State Common Retirement Fund Reduces Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World

Feb 27, 2025

Revvity Inc Stock (RVTY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$133.87
price down icon 3.49%
diagnostics_research DGX
$164.18
price down icon 3.78%
diagnostics_research LH
$225.00
price down icon 3.62%
diagnostics_research WAT
$324.92
price down icon 5.85%
diagnostics_research MTD
$1,022.66
price down icon 6.63%
diagnostics_research IQV
$154.73
price down icon 7.73%
Cap:     |  Volume (24h):